C.H. Boehringer Sohn Competitors and Similar CompaniesClear all

C.H. Boehringer Sohn's competitors and similar companies include Clinigen, Scilex Holding, Chiesi Australia and Purna Pharmaceuticals.

	C.H. Boehringer Sohn C.H. Boehringer Sohn is a holding company engaged in pharma development.	Clinigen Clinigen is a specialist pharmaceutical services company.	Scilex Holding Scilex Holding is a pharmaceutical company that specializes in drug development solutions.	Chiesi Australia Chiesi Australia is a pharmaceutical company that specializes in drug development.	Purna Pharmaceuticals Purna Pharmaceuticals is a developer, and manufacturer of pharmaceutical products.
Founding Date	Founding Date 1885	Founding Date 2010	Founding Date 2019	Founding Date 1935	Founding Date 1986
Type	Type Private	Type Private	Type Public	Type Subsidiary	Type Private
Tags	Tags Manufacturing & Industrial clinical research drug development holding company pharma	Tags Manufacturing & Industrial clinical research drug development pharma	Tags Healthcare clinical research drug development holding company pharma	Tags Healthcare drug development pharma	Tags Manufacturing & Industrial clinical research drug development pharma
Locations	Locations Ingelheim am Rhein, DE HQ	Locations Burton upon Trent, GB HQ Warriewood, AU Lyon, FR Koropi, GR Lismore, IE Chuo City, JP Singapore, SG see more	Locations HQ	Locations Melbourne, AU HQ	Locations Puurs, BE HQ
Employees	Employees 52,000	Employees 586	Employees N/A	Employees 433% increase	Employees 1442% increase
Financial
Revenue (est.)	Revenue (est.) €19.6b (FY, 2020)	Revenue (est.) £562.2m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods €2.6b (FY, 2020)	Cost of goods £301.2m (FY, 2021)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit €17b (FY, 2020)	Gross profit £261m (FY, 2021)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income €3.1b (FY, 2020)	Net income £38.7m (FY, 2021)	Net income N/A	Net income N/A	Net income N/A